Glossary of Terms¶
Analytical Methods¶
| Term | Definition |
|---|---|
| Amino Acid Analysis (AAA) | A quantitative analytical technique that hydrolyzes a peptide into its constituent amino acids, then separates, derivatizes, and quantifies them to determine peptide content and confirm the amino acid composition matches the expected sequence. |
| Electrospray Ionization Mass Spectrometry (ESI-MS) | A soft ionization mass spectrometry technique that produces multiply charged ions from peptide samples in solution, enabling accurate molecular weight determination (±1.0 Da) without significant fragmentation. |
| High-Performance Liquid Chromatography (HPLC) | An analytical separation technique that passes a peptide sample through a column packed with stationary phase under high pressure; the most common method for determining peptide purity, typically using reversed-phase (RP) C18 columns with UV detection at 214 nm (peptide bond absorbance). |
| Karl Fischer Titration | A quantitative analytical method for determining water content in a sample through coulometric or volumetric titration using iodine generated or consumed in the Karl Fischer reaction; reported as percentage water content. |
| MALDI-TOF Mass Spectrometry | Matrix-Assisted Laser Desorption/Ionization Time-of-Flight mass spectrometry; an alternative to ESI-MS that uses a laser to ionize peptide samples embedded in a crystalline matrix, producing predominantly singly charged ions for mass analysis. |
| LAL Test (Limulus Amebocyte Lysate) | An endotoxin detection assay derived from horseshoe crab blood cells that coagulates in the presence of bacterial endotoxins (lipopolysaccharides); results reported in Endotoxin Units per milligram (EU/mg), with a typical specification of ≤1.0 EU/mg for research peptides. |
| Peptide Content | The actual mass of peptide present in a lyophilized sample relative to total mass, accounting for counterions (acetate, TFA), residual water, and salts; determined by amino acid analysis or nitrogen content analysis and distinct from HPLC purity. |
| Residual Solvent Analysis | Determination of organic solvent residues remaining from peptide synthesis and purification (cleavage, HPLC, lyophilization) using headspace gas chromatography (GC); limits established per ICH Q3C guidelines for each solvent class. |
| UV-Vis Spectroscopy | Ultraviolet-visible spectrophotometry measuring absorbance across 190–800 nm; used for peptide concentration determination (280 nm for aromatic residues, 214 nm for peptide bonds) and for confirming GHK-Cu copper complexation (λmax ~590–610 nm). |
| System Suitability | A set of tests performed before analytical HPLC runs to verify that the chromatographic system (pump, column, detector) is performing adequately; typically includes resolution, theoretical plates, tailing factor, and injection precision parameters. |
Peptide Chemistry¶
| Term | Definition |
|---|---|
| Solid-Phase Peptide Synthesis (SPPS) | The predominant method for synthetic peptide production, in which a peptide chain is assembled stepwise on an insoluble resin support; amino acids are added sequentially from C-terminus to N-terminus using Fmoc (9-fluorenylmethoxycarbonyl) or Boc (tert-butyloxycarbonyl) protection strategies. |
| Fmoc Chemistry | A widely used SPPS strategy employing the base-labile Fmoc protecting group for temporary Nα-amino protection; deprotection is achieved with piperidine, and final peptide cleavage from the resin uses trifluoroacetic acid (TFA). |
| Albumin Binding | A pharmacokinetic half-life extension strategy in which a fatty acid moiety (e.g., C18 or C20 diacid) conjugated to a peptide reversibly binds to serum albumin, reducing renal clearance and protecting the peptide from rapid proteolytic degradation. |
| Aib (α-Aminoisobutyric Acid) | A non-proteinogenic amino acid (2-aminoisobutyric acid, C₄H₉NO₂) featuring a quaternary α-carbon with two methyl substituents; incorporation into GLP-1 analogs at position 8 confers resistance to dipeptidyl peptidase-4 (DPP-4) enzymatic cleavage. |
| DPP-4 Resistance | Structural resistance to cleavage by dipeptidyl peptidase-4, the primary enzyme responsible for rapid inactivation of native GLP-1 (half-life ~2 minutes); achieved through amino acid substitutions at the DPP-4 cleavage site (position 8, typically Ala→Aib or similar modification). |
| Lyophilization (Freeze-Drying) | A dehydration process in which a peptide solution is frozen and then subjected to high vacuum, causing ice to sublimate directly from solid to vapor; produces a stable, dry powder with low residual moisture suitable for long-term storage. |
| Counterion | The ionic species associated with ionizable groups on a peptide (typically TFA from cleavage or acetate from HPLC purification and salt exchange); acetate salt forms are preferred for most research applications due to biocompatibility and lower residual toxicity compared to TFA. |
| Cyclization | Formation of a covalent bond creating a cyclic peptide structure (head-to-tail, side chain-to-side chain, or side chain-to-terminus); may improve metabolic stability, receptor selectivity, and conformational constraint relative to the linear peptide. |
| Fatty Acid Conjugation | Covalent attachment of a fatty acid chain (e.g., C18 diacid, C20 eicosanedioic acid) to a peptide via a linker (typically gamma-glutamyl-polyethylene glycol); the primary strategy for extending peptide half-life through albumin binding. |
| Trifluoroacetic Acid (TFA) | A strong acid used in SPPS for final peptide cleavage and deprotection; residual TFA remains as the counterion unless exchanged for acetate during purification, requiring ion chromatography verification in the final product. |
Quality Control Terminology¶
| Term | Definition |
|---|---|
| Certificate of Analysis (COA) | A document issued by the quality control unit for each manufactured batch, certifying that the product has been tested against defined specifications and meets acceptance criteria; includes test results, method references, specification limits, and QC authorization. |
| Material Safety Data Sheet (MSDS/SDS) | A standardized document (16-section GHS format) providing information on the hazards, safe handling, storage, accidental release measures, toxicology, and regulatory status of a chemical product; supplied with every shipment. |
| Batch Record | A comprehensive document (or set of documents) capturing every step of the manufacturing process for a specific batch, including material lot numbers, process parameters, in-process controls, yields, deviations, and QC release testing results. |
| Out of Specification (OOS) | A test result that falls outside the established acceptance criteria for a given specification; triggers a formal investigation per defined SOPs to determine root cause (laboratory error vs. manufacturing failure) and appropriate disposition. |
| CAPA (Corrective and Preventive Action) | A quality system process for addressing identified nonconformities: Corrective Action addresses the immediate root cause of an existing issue; Preventive Action identifies and mitigates potential future occurrences of similar issues. |
| Retention Sample | A representative sample from each manufactured batch retained under defined storage conditions for a specified period (typically 3 years) for potential future re-testing, investigation, or regulatory inquiry. |
| Endotoxin Limit | The maximum acceptable level of bacterial endotoxins (lipopolysaccharides) in a product, expressed in Endotoxin Units per milligram (EU/mg); a typical specification for research peptides is ≤1.0 EU/mg, determined by LAL kinetic chromogenic assay. |
| Peptide Content vs. Purity | Purity (HPLC) measures the proportion of the target peptide relative to peptide-related impurities in the sample. Peptide content measures the actual mass of peptide relative to total lyophilized powder mass (accounting for water, counterions, salts). Both are critical specifications: high purity does not guarantee high peptide content. |
| ICH Guidelines | Internationally harmonized technical guidelines published by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use; key references include ICH Q2 (analytical validation), Q3C (residual solvents), and Q7 (GMP for active pharmaceutical ingredients). |
| Release Testing | The final set of analytical tests performed on a finished batch prior to its release for distribution; results are documented on the COA and reviewed by the Quality Unit as part of the batch disposition decision. |
Supply Chain & Procurement¶
| Term | Definition |
|---|---|
| Incoterms | International Commercial Terms published by the International Chamber of Commerce (ICC) defining the responsibilities of buyers and sellers for the delivery of goods; commonly used terms include DAP (Delivered at Place) and FCA (Free Carrier). |
| Commercial Invoice | The primary customs document for international trade, detailing the exporter, importer, goods description, HS codes, declared value, currency, incoterms, and country of origin; used by customs authorities to assess duties and taxes. |
| Harmonized System (HS) Code | An internationally standardized numerical code (6–10 digits) for classifying traded products; assigned by the World Customs Organization and used by customs authorities worldwide to determine applicable duties, taxes, and regulatory requirements. |
| Proforma Invoice | A preliminary bill of sale sent to a buyer in advance of a shipment, describing the goods, quantities, and agreed prices; used for payment processing and import license applications but is not a demand for payment. |
| Cold Chain Logistics | A temperature-controlled supply chain for products requiring defined temperature ranges during storage and transit (typically 2–8°C for refrigerated products); includes validated insulated containers, phase-change coolant packs, and temperature monitoring devices. |
| Letter of Credit (L/C) | A payment mechanism issued by a bank guaranteeing that a seller will receive payment from a buyer on time and for the correct amount, provided the seller meets specified terms and conditions; commonly used for high-value international transactions (>$50,000). |
| MOQ (Minimum Order Quantity) | The smallest quantity of a product that a supplier is willing to sell in a single transaction; established based on production economics, packaging constraints, and business policy. |
| OEM (Original Equipment Manufacturing) | A manufacturing arrangement in which a producer manufactures products that are marketed and sold under another company's brand; in peptide procurement, OEM services include custom labeling, branded packaging, and custom documentation. |
Regulatory¶
| Term | Definition |
|---|---|
| Research Use Only (RUO) | A regulatory classification for products intended exclusively for laboratory research and investigation; RUO products are not manufactured under drug GMP, not validated for clinical diagnostic or therapeutic use, and must bear clear labeling stating this restriction. |
| Good Manufacturing Practice (GMP) | A system of regulations, codes, and guidelines ensuring that products are consistently produced and controlled according to quality standards; for active pharmaceutical ingredients, ICH Q7 provides the framework; pharmaceutical drug GMP for finished products is defined in 21 CFR 210/211 (US) and EU GMP guidelines. |
| Investigational New Drug (IND) | A regulatory submission to the FDA (or equivalent authority) requesting authorization to administer an investigational drug to humans in a clinical trial; RUO peptides have not been manufactured under IND-enabling GMP and are not authorized for clinical investigation without appropriate regulatory filings. |
| Regulatory Starting Material (RSM) | The point in a synthetic process where GMP requirements begin to apply for pharmaceutical manufacturing; for peptide APIs, the RSM is typically the first amino acid loaded onto the resin or the first protected amino acid derivative introduced into the synthesis. |
This glossary is maintained and expanded as the peptide research and procurement landscape evolves. Last updated: August 2026.